STEMRIM |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 470 JPY | -1.88% |
|
-0.63% | -18.69% |
| 03:13pm | StemRIM to Seek Shareholders' Approval on Capital Stock Reduction | MT |
| 03-13 | StemRIM Announces Initiation of Phase 2 Clinical Trial for Redasemtide in Ischemic Cardiomyopathy | CI |
StemRIM Inc. is a Japan-based company mainly engaged in the regenerative medicine business. The Company is engaged in the development and research of medicines based on new action mechanism to promote functional regeneration and healing of biological tissue damaged and lost function due to injury or illness. The Companyâs main product is stem cell regeneration-inducing medicine. The stem cell regeneration-inducing medicine is a medicine which can obtain the same therapeutic effect as regenerative medicine only by administering the medicine without using living cells and tissues.
Sector
Pharmaceuticals
Calendar
12/06/2024
- Q3 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -18.69% | 189M | |
| -3.35% | 88.91B | |
| +2.76% | 41.25B | |
| -13.92% | 31.99B | |
| +50.51% | 24.73B | |
| -15.25% | 15.54B | |
| -39.93% | 12.07B | |
| -9.08% | 12.05B | |
| -14.80% | 12.02B | |
| +6.22% | 8.84B |
- Stock Market
- Equities
- 4599 Stock
- Funds and ETFs StemRIM
